The possible association of in vivo leukocyte-platelet heterophilic aggregate formation and the development of diabetic angiopathy

M. Kaplar, J. Kappelmayer, A. Veszpremi, K. Szabo, M. Udvardy

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Circulating leukocyte-platelet heterophilic aggregates produce procoagulant, oxidative and mitogenic substances, and can cause microembolism in capillaries as well as acute arterial thrombosis. Our aim was to determine if there was any difference in the number of circulating heterophilic aggregates between diabetic patients and controls, if the formation of aggregates correlated with the actual HgbA1c level, duration of diabetes and postprandial rise in serum glucose level, with different vascular complications and whether decreasing postprandial serum glucose had any effect on heterophilic aggregate formation. The number of circulating heterophilic aggregates was measured in 90 diabetic patients (Type 1, 29; Type 2, 61) and in 23 control subjects by a flow-cytometric assay, and the result was given as percentage of the respective leukocyte subsets. There was no significant difference in lymphocyte-platelet and neutrophil-platelet aggregate number in patients and controls; however, there was a significant difference in the percentage of monocyte-platelet aggregates between the diabetic and control group (Type 1, 43.0 ± 17.8; Type 2, 34.9 ± 12.5; control, 24.6 ± 8.2; P <0.01 and P <0.5, respectively). Patients with proliferative retinopathy and nephropathy showed the highest number of monocyte-platelet aggregates. No significant correlation was, however, found with HgbA1c. In Type 2 diabetes a non-significant, but remarkable, tendency between elevation of postprandial serum glucose levels and platelet-monocyte aggregate formation was observed and acarbose seemed to be effective in decreasing both. This study provides further support that heterophilic aggregates might have role in the pathogenesis of diabetic vascular complications.

Original languageEnglish
Pages (from-to)419-422
Number of pages4
JournalPlatelets
Volume12
Issue number7
DOIs
Publication statusPublished - 2001

Fingerprint

Diabetic Angiopathies
Leukocytes
Blood Platelets
Monocytes
Platelet Count
Glucose
Serum
Acarbose
Type 2 Diabetes Mellitus
Blood Vessels
Neutrophils
Thrombosis
Lymphocytes
Control Groups

ASJC Scopus subject areas

  • Hematology
  • Cell Biology

Cite this

The possible association of in vivo leukocyte-platelet heterophilic aggregate formation and the development of diabetic angiopathy. / Kaplar, M.; Kappelmayer, J.; Veszpremi, A.; Szabo, K.; Udvardy, M.

In: Platelets, Vol. 12, No. 7, 2001, p. 419-422.

Research output: Contribution to journalArticle

@article{fe2cedc2542740ce82824d3e04095582,
title = "The possible association of in vivo leukocyte-platelet heterophilic aggregate formation and the development of diabetic angiopathy",
abstract = "Circulating leukocyte-platelet heterophilic aggregates produce procoagulant, oxidative and mitogenic substances, and can cause microembolism in capillaries as well as acute arterial thrombosis. Our aim was to determine if there was any difference in the number of circulating heterophilic aggregates between diabetic patients and controls, if the formation of aggregates correlated with the actual HgbA1c level, duration of diabetes and postprandial rise in serum glucose level, with different vascular complications and whether decreasing postprandial serum glucose had any effect on heterophilic aggregate formation. The number of circulating heterophilic aggregates was measured in 90 diabetic patients (Type 1, 29; Type 2, 61) and in 23 control subjects by a flow-cytometric assay, and the result was given as percentage of the respective leukocyte subsets. There was no significant difference in lymphocyte-platelet and neutrophil-platelet aggregate number in patients and controls; however, there was a significant difference in the percentage of monocyte-platelet aggregates between the diabetic and control group (Type 1, 43.0 ± 17.8; Type 2, 34.9 ± 12.5; control, 24.6 ± 8.2; P <0.01 and P <0.5, respectively). Patients with proliferative retinopathy and nephropathy showed the highest number of monocyte-platelet aggregates. No significant correlation was, however, found with HgbA1c. In Type 2 diabetes a non-significant, but remarkable, tendency between elevation of postprandial serum glucose levels and platelet-monocyte aggregate formation was observed and acarbose seemed to be effective in decreasing both. This study provides further support that heterophilic aggregates might have role in the pathogenesis of diabetic vascular complications.",
author = "M. Kaplar and J. Kappelmayer and A. Veszpremi and K. Szabo and M. Udvardy",
year = "2001",
doi = "10.1080/09537100120078368",
language = "English",
volume = "12",
pages = "419--422",
journal = "Platelets",
issn = "0953-7104",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - The possible association of in vivo leukocyte-platelet heterophilic aggregate formation and the development of diabetic angiopathy

AU - Kaplar, M.

AU - Kappelmayer, J.

AU - Veszpremi, A.

AU - Szabo, K.

AU - Udvardy, M.

PY - 2001

Y1 - 2001

N2 - Circulating leukocyte-platelet heterophilic aggregates produce procoagulant, oxidative and mitogenic substances, and can cause microembolism in capillaries as well as acute arterial thrombosis. Our aim was to determine if there was any difference in the number of circulating heterophilic aggregates between diabetic patients and controls, if the formation of aggregates correlated with the actual HgbA1c level, duration of diabetes and postprandial rise in serum glucose level, with different vascular complications and whether decreasing postprandial serum glucose had any effect on heterophilic aggregate formation. The number of circulating heterophilic aggregates was measured in 90 diabetic patients (Type 1, 29; Type 2, 61) and in 23 control subjects by a flow-cytometric assay, and the result was given as percentage of the respective leukocyte subsets. There was no significant difference in lymphocyte-platelet and neutrophil-platelet aggregate number in patients and controls; however, there was a significant difference in the percentage of monocyte-platelet aggregates between the diabetic and control group (Type 1, 43.0 ± 17.8; Type 2, 34.9 ± 12.5; control, 24.6 ± 8.2; P <0.01 and P <0.5, respectively). Patients with proliferative retinopathy and nephropathy showed the highest number of monocyte-platelet aggregates. No significant correlation was, however, found with HgbA1c. In Type 2 diabetes a non-significant, but remarkable, tendency between elevation of postprandial serum glucose levels and platelet-monocyte aggregate formation was observed and acarbose seemed to be effective in decreasing both. This study provides further support that heterophilic aggregates might have role in the pathogenesis of diabetic vascular complications.

AB - Circulating leukocyte-platelet heterophilic aggregates produce procoagulant, oxidative and mitogenic substances, and can cause microembolism in capillaries as well as acute arterial thrombosis. Our aim was to determine if there was any difference in the number of circulating heterophilic aggregates between diabetic patients and controls, if the formation of aggregates correlated with the actual HgbA1c level, duration of diabetes and postprandial rise in serum glucose level, with different vascular complications and whether decreasing postprandial serum glucose had any effect on heterophilic aggregate formation. The number of circulating heterophilic aggregates was measured in 90 diabetic patients (Type 1, 29; Type 2, 61) and in 23 control subjects by a flow-cytometric assay, and the result was given as percentage of the respective leukocyte subsets. There was no significant difference in lymphocyte-platelet and neutrophil-platelet aggregate number in patients and controls; however, there was a significant difference in the percentage of monocyte-platelet aggregates between the diabetic and control group (Type 1, 43.0 ± 17.8; Type 2, 34.9 ± 12.5; control, 24.6 ± 8.2; P <0.01 and P <0.5, respectively). Patients with proliferative retinopathy and nephropathy showed the highest number of monocyte-platelet aggregates. No significant correlation was, however, found with HgbA1c. In Type 2 diabetes a non-significant, but remarkable, tendency between elevation of postprandial serum glucose levels and platelet-monocyte aggregate formation was observed and acarbose seemed to be effective in decreasing both. This study provides further support that heterophilic aggregates might have role in the pathogenesis of diabetic vascular complications.

UR - http://www.scopus.com/inward/record.url?scp=0035185152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035185152&partnerID=8YFLogxK

U2 - 10.1080/09537100120078368

DO - 10.1080/09537100120078368

M3 - Article

VL - 12

SP - 419

EP - 422

JO - Platelets

JF - Platelets

SN - 0953-7104

IS - 7

ER -